News and Features
FDA Updates Rilpivirine (Edurant) Labeling
“On May 1, 2014, FDA approved changes to the Edurant (rilpivirine) label to include drug-drug interaction with rilpivirine and metformin and rilpivirine and rifabutin.
“Under section 2 Dosage and Administration:
“Rifabutin Co-administration: For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) once daily, taken with a meal. When rifabutin co-administration is stopped, the EDURANT dose should be decreased to 25 mg once daily, taken with a meal.
“Rilpivirine did not have a clinically significant effect on the pharmacokinetics of metformin.”
The revised label is available at the FDA website.
More information is available:
May 18 is HIV Vaccine Awareness Day
HIV Vaccine Awareness Day is observed each year on May 18. The day serves as an occasion to recognize and thank the many volunteers, community members, health professionals, and scientists working together toward finding an HIV vaccine. This day also serves to highlight the importance of HIV vaccine research.
We invite you to explore our HIV Vaccine Awareness Day webpage [en español] to learn more about this observance and HIV vaccine research that is currently in progress.
May 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day
May 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day. The annual observance was founded by the Banyan Tree Project, with support from the Centers for Disease Control and Prevention (CDC). The goal of the project is to stop HIV/AIDS-related stigma in Asian and Pacific Islander communities. According to the Banyan Tree Project, “… this type of discrimination prevents A&PIs [Asians and Pacific Islanders] from getting tested for HIV and from getting health care and other services they need to stay healthy.”
Explore our National Asian and Pacific Islander HIV/AIDS Awareness Day webpage [en español] to learn more about the observance and find related information.